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Abstract
Introduction Theoretical risks of biologic agents remain under study.
Objective The aim of this study was to integrate 1-year safety data from 12 ustekinumab registrational trials.
Methods Patients had moderate-to-severe plaque psoriasis, active psoriatic arthritis (PsA) (± methotrexate), or moderate-
to-severe Crohn’s disease (CD; failed/intolerant of immunomodulators/corticosteroids). Psoriatic patients received subcu-
taneous ustekinumab 45/90 mg or placebo, generally at week 0, week 4, then every 12 weeks thereafter, while those with 
CD received a single intravenous ustekinumab dose (130 mg or weight range-based dosing of approximately 6 mg/kg) or 
placebo induction dose at week 0, followed by subcutaneous ustekinumab 90 mg at week 8 and every 8/12 weeks thereafter. 
The incidence rates of a priori-defined safety events were integrated post hoc (adjusted for duration of follow-up, reported 
per 100 patient-years [PYs]).
Results Among 6280 enrolled patients, 5884 ustekinumab-treated patients (psoriasis: 3117; PsA: 1018; CD: 1749) contrib-
uted 4521 PYs versus 674 PYs in placebo-treated patients through year 1 (829 PYs and 385 PYs during 8- to 16-week con-
trolled periods). Combined across diseases among ustekinumab- versus placebo-treated patients, respective incidences/100 
PYs (95% confidence intervals) of infections were 125.4 (122.2–128.7) versus 129.4 (120.9–138.3) through year 1, and 
not meaningfully increased in patients who did versus those who did not receive methotrexate (92.5 [84.2–101.5] vs. 115.3 
[109.9–121.0]), or significantly increased in patients who did versus those who did not receive corticosteroids (116.3 
[107.3–125.9] vs. 107.3 [102.0–112.8]) at baseline. Major adverse cardiovascular events (0.5 [0.3–0.7] vs. 0.3 [0.0–1.1]), 
malignancies (0.4 [0.2–0.6] vs. 0.2 [0.0–0.8]), and deaths (0.1 [0.0–0.3] vs. 0.0 [0.0–0.4]) were rare across indications.
Conclusions Ustekinumab demonstrated a favorable and consistent safety profile across registrational trials in approved 
indications.
Trial Registrations ClinicalTrials.gov identifier: NCT00320216, NCT00267969, NCT00307437, NCT00454584, 
NCT00267956, NCT01009086, NCT01077362, NCT00265122, NCT00771667, NCT01369329, NCT01369342, and 
NCT01369355.
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Key Points 
When data from 12 registrational trials conducted in 
patients with psoriasis, psoriatic arthritis (PsA), and 
Crohn’s disease (CD) were combined, discontinuations 
due to adverse events (AEs) and incidences of AEs, 
serious AEs, and infections were consistent between 
ustekinumab- and placebo-treated patients through up to 
1 year of follow-up.
Among ustekinumab-treated patients, incidences of 
major adverse cardiovascular events, malignancies, 
and deaths through 1 year were low (≤ 0.5/100 patient-
years); the occurrence of infections through 1 year did 
not appear to be affected by baseline methotrexate or 
corticosteroid use.
In this integrated cohort of 5884 ustekinumab-treated 
patients, ustekinumab demonstrated a favorable inte-
grated safety profile, consistent with previous safety 
observations from trials within each indication.
1 Introduction
Although biological therapies such as antagonists of tumor 
necrosis factor (TNF)-α or interleukins (IL)-12/23 generally 
offer improved efficacy over conventional immunosuppres-
sants (IMMs) in treating immune-mediated inflammatory 
disorders, theoretical risks associated with impaired immune 
surveillance remain under study. Furthermore, patients with 
immune-mediated inflammatory disorders can present with 
comorbidities, including cardiovascular diseases, obesity, 
malignancy, and chronic infections, that should inform the 
decision to utilize a biologic agent [1, 2].
Ustekinumab is a fully human immunoglobulin G1k mon-
oclonal antibody that specifically blocks the shared p40 sub-
unit of IL-12 and IL-23 [3], naturally occurring regulatory 
cytokines involved in inflammatory and immune responses, 
natural killer cell activation, and signaling for downstream 
effector cytokine production (e.g. TNF, IL-17, IL-22) [4].
Multiple randomized controlled trials (RCTs) (Table 1) 
have established the efficacy of ustekinumab for moderate-
to-severe psoriasis [5–7], active psoriatic arthritis (PsA) 
[8–10], and moderate-to-severe Crohn’s disease (CD) [11]. 
The safety of ustekinumab in psoriasis has been assessed 
through up to 5 years of continuous follow-up in two large 
RCT extensions and up to 8 years in the Psoriasis Longi-
tudinal and Assessment Registry (PSOLAR) of > 12,000 
psoriasis patients (35.7% with self-reported PsA) [12–18]. 
No increased risk of malignancies, serious major adverse 
cardiovascular events (MACEs), serious infections (SIs), or 
mortality has been observed across RCT- or registry-derived 
analyses. These longer-term data are consistent with safety 
findings from psoriasis registrational trials [5–7] and addi-
tional registries conducted in psoriatic patients [19, 20]. 
Consistent ustekinumab safety was observed in two pivotal 
PsA RCTs, one with a long-term extension through up to 
2 years (PSUMMIT-1) [8–10]. While preliminary safety 
findings in CD patients also show similarities through 1 
versus 2 years of ustekinumab, data are limited [11, 21, 22].
We conducted this first integrated analysis of usteki-
numab safety data from 12 registrational RCTs to better 
understand the overall safety profile of ustekinumab, given 
that diverse disease states in heterogeneous populations 
receiving different dosing regimens and concomitant medi-
cations may carry differing risks of adverse reactions, and 
considering that rare safety events may only be identified as 
larger safety databases become available. When combined 
across the approved psoriasis, PsA, and CD indications, 
approximately 70% and 36% of the 5884 patients receiv-
ing ustekinumab were treated for ≥ 6 months and ≥ 1 year, 
respectively.
2  Patients and Methods
2.1  Trial Designs
Details of the 12 randomized, placebo- or active compara-
tor-controlled trials comprising the ustekinumab phase II/III 
registrational development program for psoriasis [5–7, 23], 
PsA [8, 9, 24], and CD [11, 21, 22] have been reported (Clin-
icalTrials.gov identifier: NCT00320216, NCT00267969, 
NCT00307437, NCT00454584, NCT00267956, NCT0 
1009086, NCT01077362, NCT00265122, NCT00771667, 
NCT01369329, NCT01369342, and NCT01369355) 
(Table 1).
Trials conducted in patients with chronic moderate-to-severe 
psoriasis (Psoriasis Area and Severity Index [PASI] score ≥ 12; 
psoriasis involving ≥ 10% of body surface area) include a phase 
II trial (NCT00320216) in which patients received a single 
dose or four weekly doses of ustekinumab 45 or 90 mg by sub-
cutaneous injection, and three phase III trials (PHOENIX-1 
[NCT00267969], PHOENIX-2 [NCT00307437], and ACCEPT 
[NCT00454584]) in which patients received ustekinumab 45 
or 90 mg by subcutaneous injection at week 0, week 4, and 
then generally every 12 weeks. PHOENIX-1 had a randomized 
withdrawal and re-treatment phase, some patients in PHOE-
NIX-2 later received every-8-weeks dosing, and further dosing 
in ACCEPT depended on response at week 12. Because etaner-
cept was the comparator in the controlled period of ACCEPT, 
only ustekinumab-treated, but not etanercept-treated, patients 
from ACCEPT were included in these analyses (Table 1). 
Participants could not receive concomitant oral IMMs or oral 
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Table 1  Overview of RCTs included in integrated ustekinumab safety analyses
Study phase/identifier 
(dates)
Treatment groups/numbers of patients
Moderate-to-severe plaque psoriasis (no concomitant CSs/IMMs)
 Phase II/
 NCT00320216
 (11/2003–3/2005) [23]
Placebo weekly × 4 SC doses (n = 64)a
Ustekinumab 45 mg single SC dose—week 0 (n = 64)
Ustekinumab 90 mg single SC dose—week 0 (n = 64)
Ustekinumab 45 mg weekly × 4 SC doses (n = 64)
Ustekinumab 90 mg weekly × 4 SC doses (n = 64)
 Phase III/PHOENIX-1
 NCT00267969
 (12/2005–5/2011) [5]
Placebo SC (weeks 0 and 4) → ustekinumab 45 mg SC—weeks 12 and 16 then q12w (n = 123)
Placebo SC (weeks 0 and 4) → ustekinumab 90 mg SC—weeks 12 and 16 then q12w (n = 120)
Ustekinumab 45 mg SC—weeks 0 and 4 then q12w (n = 255)
Ustekinumab 90 mg SC—weeks 0 and 4 then q12w (n = 256)
At week 28, PASI75 responders continued 45 or 90 mg, q12w; PASI50–75 partial responders switched to 45 or 
90 mg q8w
At week 40, PASI75 responders initially randomized to ustekinumab were re-randomized to placebo or 45/90 mg 
q12w; PASI75 responders initially randomized to placebo withdrew from treatment; PASI75 partial responders 
initially randomized to placebo switched from q12w → q8w dosing
 Phase III/PHOENIX-2
 NCT00307437
 (5/2005–10/2011) [6]
Placebo SC (weeks 0 and 4) → ustekinumab 45 mg SC—weeks 12 and 16 then q12w (n = 197)
Placebo SC (weeks 0 and 4) → ustekinumab 90 mg SC—weeks 12 and 16 then q12w (n = 195)
Ustekinumab 45 mg SC—weeks 0 and 4 then q12w (n = 409)
Ustekinumab 90 mg SC—weeks 0 and 4 then q12w (n = 411)
At week 28, PASI50–75 partial responders were randomized to maintain their originally assigned dose (45 or 
90 mg) at q12w intervals or dose-adjusted to q8w
 Phase III/ACCEPT
 NCT00454584
 (3/2007–1/2009) [7]
Etanercept 50 mg SC twice weekly for 12 weeks (n = 347)b 
Ustekinumab 45 mg SC—weeks 0 and 4 (n = 209)b
Ustekinumab 90 mg SC—weeks 0 and 4 (n = 347)b
Active psoriatic arthritis (with or without CSs/MTX)
 Phase II/
 NCT00267956
 (12/2005–9/2007) [24]
Placebo SC—weeks 0, 1, 2, and 3 → ustekinumab 90 mg SC—weeks 12 and 16 (n = 70)
Ustekinumab 90 mg SC—weeks 0, 1, 2, and 3 → placebo SC—weeks 12 and 16 (n = 76)
Inclusion of up to 25% of patients previously treated with anti-TNF agents allowed
 Phase III/PSUMMIT-1
 NCT01009086
 (12/2009–5/2013) [8]
Placebo SC—weeks 0, 4, 16, and 20) → ustekinumab 45 mg SC—weeks 24 and 28 then q12w (n = 206)
Ustekinumab 45 mg SC—weeks 0 and 4 then q12w (n = 205)
Ustekinumab 90 mg SC—weeks 0 and 4 then q12w (n = 204)
Naïve to anti-TNF agents
 Phase III/PSUMMIT-2
 NCT01077362
 (3/2010–11/2012) [9]
Placebo SC—weeks 0, 4, 16, and 20 → ustekinumab 45 mg SC—weeks 24 and 28 then q12w (n = 104)
Ustekinumab 45 mg SC—weeks 0 and 4 then q12w (n = 103)
Ustekinumab 90 mg SC—weeks 0 and 4 then q12w (n = 105)
Inclusion of 50–60% of patients previously treated with anti-TNF agents allowed
Moderately-to-severely active Crohn’s Disease (with or without concomitant CSs/IMMs)
 Phase IIa
 NCT00265122
 (4/2004–10/2006) [21]
Population 1—active disease despite treatment with conventional therapy (n = 104):
 Ustekinumab 90 mg SC—weeks 0, 1, 2 and 3; placebo SC—weeks 8, 9, 10, and 11 (n = 25)
 Placebo SC—weeks 0, 1, 2, and 3; ustekinumab 90 mg SC—weeks 8, 9, 10, and 11 (n = 26)
 Ustekinumab 4.5 mg/kg IV—week 0; placebo IV—week 8 (n = 26)
 Placebo IV—week 0; ustekinumab 4.5 mg/kg IV—week 8 (n = 27)
Population 2—failure to respond to, or loss of response to, infliximab at the maximum approved dose and treatment 
regimen for CD (n = 27):
 Ustekinumab 90 mg SC—weeks 0, 1, 2, and 3 (n = 14)
 Ustekinumab 4.5 mg/kg IV—week 0 (n = 13)
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corticosteroids (CSs) during the psoriasis studies. Prior treat-
ment with certain biologics, with appropriate washout, was 
permitted (Tables 1 and 2).
In patients with PsA, one phase II trial (NCT00267956) 
and two phase III trials (PSUMMIT-1 [NCT01009086] and 
PSUMMIT-2 [NCT01077362]) included patients with active 
disease for ≥ 6 months and an inadequate response or intol-
erance to previous or current IMMs and/or non-steroidal 
anti-inflammatory drugs. Patients could receive concomitant 
therapy with stable regimens of methotrexate (approximately 
45% of patients) or CSs (approximately 14% of patients). 
PSUMMIT-1 excluded patients who had previously received 
anti-TNF agents, while the phase II and PSUMMIT-2 trials 
allowed enrollment of up to 25% and 50–60%, respectively, 
of patients previously treated with one or more anti-TNF 
agents. Phase III trials evaluated ustekinumab 45 and 90 mg 
administered by subcutaneous injection at week 0, week 4, 
and then every 12 weeks (Table 1).
CD Crohn’s disease, CSs corticosteroids, IMMs immunomodulators, IV intravenous, MTX methotrexate, PASI Psoriasis Area and Severity Index, 
PGA Physician’s Global Assessment, q8/12w every 8/12 weeks, RCT randomized controlled trial, SC subcutaneous, TNF tumor necrosis factor
a At week 20, patients in the placebo group received a single dose of ustekinumab 90 mg SC
b Treatment after week 12 depended on PGA response at week 12 and initial treatment assignment (etanercept non-responders received usteki-
numab 90 mg, ustekinumab non-responders received an additional ustekinumab dose at week 16, all responders had treatment interrupted fol-
lowed by ustekinumab re-treatment if psoriasis recurred). Etanercept patients were not included in these analyses through week 12
c 28 patients who received a previous IV formulation were excluded from the efficacy analyses and some safety analyses of the individual studies 
but were included in these integrated safety analyses
d 12 patients who received a previous IV formulation were excluded from the efficacy analyses and some safety analyses of the individual studies 
but were included in these integrated safety analyses
e Those continuing placebo 16 weeks after IV ustekinumab induction were subsequently included in the placebo group for the 1-year analyses 
(unless/until they met loss of response criteria and crossed back to ustekinumab [38% of the 133 patients])
Table 1  (continued)
Study phase/identifier 
(dates)
Treatment groups/numbers of patients
 Phase IIb/CERTIFI
 NCT00771667
Randomized IV induction phase:
 (12/2008–12/2010) [22]  Placebo (n = 132); ustekinumab 1 mg/kg (n = 131); ustekinumab 3 mg/kg (n = 132); ustekinumab 6 mg/kg (n = 131)
SC maintenance phase (based on clinical response to IV induction at week 6):
 Responders—randomized to: placebo—weeks 8 and 16 (n = 73); ustekinumab 90 mg SC—weeks 8 and 16 (n = 72)
 Non-responders—randomized to: ustekinumab 90 mg SC (n = 109); placebo (n = 110)
 Non-randomized patients (n = 113): placebo—weeks 8 and 16 (responders to placebo IV induction, n = 28); Usteki-
numab 270 mg SC—week 8, and 90 mg SC—week 16 (non-responders to placebo IV induction, n = 85)
Patients who did not respond initially, responded initially but then lost response, or were intolerant of prior inflixi-
mab, adalimumab, or certolizumab pegol
 Phase III/UNITI-1
 NCT01369329
 (7/2011–7/2013) [11]
Single IV induction dose at week 0 (n = 741; 769  totalc): placebo (n = 247); ustekinumab 130 mg (n = 245); tiered 
(weight-based) ustekinumab doses approximately 6 mg/kg (n = 249)
Patients who did not respond initially, responded initially but then lost response, or were intolerant of prior inflixi-
mab, adalimumab, or certolizumab pegol
 Phase III/UNITI-2
 NCT01369342
 (7/2011–10/2014) [11]
Single IV induction dose at week 0 (n = 628; 640  totald):
 Placebo (n = 210); ustekinumab 130 mg (n = 209); tiered ustekinumab doses approximately 6 mg/kg (n = 209)
Patients had active inflammation and demonstration of inadequate response to, or failure to tolerate, CSs/IMMs; 
patients with CS dependence and who received but did not fail a TNF antagonist were allowed
 Phase III/IM-UNITI
 NCT01369355
 (9/2011–10/2019) [11]
Randomized (responders to ustekinumab IV induction, n = 397):
 Placebo SC (n = 133);e ustekinumab 90 mg SC q12w (n = 132); ustekinumab 90 mg SC q8w (n = 132)
Non-randomized (n = 884):
 Placebo SC (responders to placebo IV induction, n = 123)
 Non-responders to ustekinumab IV induction (n = 476): ustekinumab 90 mg SC week 0 → discontinued at week 8 
(n = 221); ustekinumab 90 mg SC week 0 → 90 mg SC q8w (n = 255)
 Non-responders to placebo IV induction (n = 285): ustekinumab 130 mg IV—week 0 → discontinued at week 8 
(n = 121); ustekinumab 130 mg IV—week 0 → 90 mg SC q12w (n = 164)
Patients from both phase III induction studies could continue into this maintenance study, with the primary popula-
tion comprising responders to IV ustekinumab induction therapy
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Patients with CD were evaluated in a phase IIa proof-of-
concept trial (NCT00265122), a phase IIb dose-ranging trial 
(CERTIFI [NCT00771667]), two phase III induction trials 
(UNITI-1 [NCT01369329], UNITI-2 [NCT01369342]), 
and a phase III randomized withdrawal maintenance trial 
(IM-UNITI [NCT01369355]). In the phase III induction 
trials, patients received a single intravenous induction dose 
of ustekinumab (130 mg or weight-range-based dosing of 
approximately 6 mg/kg) or placebo at week 0, followed by 
a 90 mg subcutaneous dose administered at week 8 and 
then every 8 or every 12 weeks thereafter. Patients evalu-
ated in the CD trials included those who did not respond 
initially, responded initially but then lost response, and/or 
were intolerant to prior anti-TNF, IMM or CS treatment(s). 
Stable regimens of concomitant oral IMMs (approximately 
30% of patients), CSs (approximately 37% of patients), or 
both (approximately 10% of patients) were permitted dur-
ing study participation. Prior treatment with anti-TNF or 
other biologics, with appropriate washout, was also permit-
ted (Tables 1 and 2).
Across indications, patients underwent radiographic, 
purified protein derivative, and/or interferon-γ release assay 
Mycobacterium tuberculosis (TB) screening. In most stud-
ies, patients with latent TB could be enrolled with initia-
tion of established concomitant treatment protocols (e.g., 
isoniazid). While some of the study populations were anti-
TNF-naïve and others were anti-TNF failures as noted above, 
concomitant anti-TNF use was prohibited, with protocol-
specified prescreening washout periods (also see Table 1).
2.2  Safety Outcomes
All adverse events (AEs) were systematically captured 
throughout each trial, with safety monitoring through 
16–20 weeks after study agent discontinuation, i.e., follow-
up periods were substantially longer than treatment duration. 
Analyses included standard evaluations of AEs, serious AEs, 
AEs leading to study agent discontinuation, deaths, infec-
tions (determined by investigator), SIs, infections requiring 
treatment with oral/parenteral antibiotics, injection-site reac-
tions (ISRs) documented by the investigator, AEs temporally 
related to infusions (in CD patients), and clinical laboratory 
parameters per prespecified criteria. AEs of special interest, 
i.e., rare events selected for evaluation based on mechanistic 
plausibility or potential safety or population risks, included 
malignancies, adjudicated serious MACEs, anaphylactic 
and serum sickness-like hypersensitivity reactions, active 
TB, opportunistic infections (OIs), and serious neurologi-
cal disorders.
All preferred terms possibly consistent with seri-
ous MACEs (cardiovascular death, non-fatal myocardial 
infarction, and non-fatal stroke) were retrospectively adju-
dicated by an independent and blinded process, performed 
by the Cleveland Clinic Coordinating Center for Clinical 
Research (C5) at the Cleveland Clinic Foundation (http://
c5res earch .cleve landc linic .org/Home.aspx). Analyses were 
based on adjudicated events. For hypersensitivity reactions, 
the terms anaphylactic reaction, anaphylactic shock, ana-
phylactoid reaction, anaphylactoid shock, type I hypersen-
sitivity, and serum sickness or serum sickness-like reaction 
were utilized.
2.3  Data Analysis
Integrated safety data are presented for both the initial con-
trolled period and through approximately 1 year of exposure 
for studies conducted within each indication and combined 
across indications. After the 8- to 16-week controlled peri-
ods, some participants crossed over to ustekinumab per 
trial design; thus, patients may have been included in more 
than one treatment group for the 1-year analyses. Patients 
receiving one or more partial or full ustekinumab doses 
were subsequently included in the ustekinumab groups, 
except responders to ustekinumab induction who were sub-
sequently re-randomized to subcutaneous placebo in the 
randomized withdrawal IM-UNITI CD maintenance study. 
These patients were included in the placebo group starting at 
16 weeks (i.e., more than five half-lives) following induction 
dosing in subsequent analyses.
Specific AEs were summarized by system organ class and 
preferred term (Medical Dictionary for Regulatory Activi-
ties [MedDRA], version 17.1), according to actual treatment 
received. AE incidence rates are reported per 100 patient-
years (PYs) to adjust for differences in follow-up duration 
(referred to as ‘incidence/100 PYs’).
For malignancies, comparisons with an external database 
were conducted to determine whether event rates combined 
across indications were consistent with those expected for 
the general population. The National Institutes of Health 
Surveillance, Epidemiology, and End Results (SEER) data-
base (2000–2010; https ://seer.cance r.gov/resou rces) was 
selected to estimate expected event rates of malignancies, 
other than non-melanoma skin cancer (NMSC), in the gen-
eral US population adjusting for age, sex, and race. Cervical 
cancers in situ and NMSC are not included in the SEER 
database and were thus excluded from enumeration. Stand-
ardized incidence ratios (SIRs) were calculated as the ratio 
of observed versus expected numbers of patients with one 
or more malignancies. When the SIR and the lower bound-
ary of the surrounding 95% confidence interval (CI) exceed 
1, the observed number of cases is statistically significantly 
higher than expected.
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Table 2  Summary of baseline demographics, medical history, and concomitant medications and extent of exposure
6-MP 6-mercaptopurine, AZA azathioprine, BMI body mass index, CD Crohn’s disease, IV intravenous, PsA psoriatic arthritis, SD standard 
deviation
a Psoriasis: phase II, PHOENIX-1, PHOENIX-2, ACCEPT (immunomodulators and corticosteroids prohibited); PsA: phase II, PSUMMIT-1, 
PSUMMIT-2; CD: phase IIa (only placebo-controlled IV population), CERTIFI, UNITI-1, UNITI-2, IM-UNITI
b Not collected in CERTIFI (smoking information was collected)
c Not collected in the psoriasis phase II trial
d Corticosteroids and immunomodulators are prohibited medications for psoriasis
e Not collected in PsA studies
f Crossover patients were included in the ustekinumab columns after crossover to ustekinumab
g Psoriasis—phase II, PHOENIX-1, PHOENIX-2, ACCEPT (all through week 52); PsA—phase II (through week 36), PSUMMIT-1 (through 
week 52), PSUMMIT-2 (through week 60); CD—phase IIa (only placebo-controlled IV population in population 1; through week 28), CERTIFI 
(through week 36), UNITI-1 and UNITI-2 (through week 8 for patients who entered IM-UNITI; through week 20 for patients who did not enter 
IM-UNITI), IM-UNITI (through week 44)
h Only for CD studies
i The duration between the first and last ustekinumab administrations was ≥ 14 weeks
j The duration between the first and last ustekinumab administrations was ≥ 38 weeks
k Includes periods of placebo treatment among some ustekinumab responders who were re-randomized to placebo at maintenance and subse-
quently resumed ustekinumab treatment following loss of response
Psoriasis PsA CD All patients
Number of randomized patients, Na 3219 1073 1988 6280
Baseline demographics
 Age, years [mean (SD)] 45.6 (12.37) 47.6 (11.87) 38.6 (12.73) 43.7 (12.90)
  Male [n (%)] 2207 (68.6) 560 (52.2) 871 (43.8) 3638 (57.9)
  White [n (%)] 2960 (92.0) 1038 (96.8) 1729 (87.0) 5727 (91.2)
  Weight, kg [mean (SD)] 91.8 (22.15) 89.4 (21.07) 72.2 (19.64) 85.2 (22.99)
  BMI, kg/m2 [mean (SD)] 30.9 (6.99) 31.0 (7.13) 25.0 (6.22) 29.0 (7.32)
Medical history and current diagnoses,b[% (n/N)]
 Congestive heart  failurec [% (n/N)] 0.2 (5/2899) 1.1 (12/1073) 0.4 (7/1935) 0.4 (24/5907)
 Peripheral vascular  diseasec [% (n/N)] 1.2 (35/2899) 3.4 (36/1073) 1.5 (29/1935) 1.7 (100/5907)
 Transient ischemic  attackc [% (n/N)] 0.8 (24/2899) 1.0 (11/1073) 0.8 (15/1935) 0.8 (50/5907)
 Strokec [% (n/N)] 0.6 (17/2899) 1.4 (15/1073) 0.7 (14/1935) 0.8 (46/5907)
 Ischemic heart/coronary artery disease [% (n/N)] 3.9 (125/3219) 5.7 (61/1073) 2.3 (44/1935) 3.7 (230/6227)
 Hyperlipidemia [% (n/N)] 20.2 (649/3219) 17.6 (189/1073) 5.8 (113/1935) 15.3 (951/6227)
 Hypertension [% (n/N)] 27.5 (886/3219) 38.1 (409/1073) 13.6 (264/1935) 25.0 (1559/6227)
 Diabetes mellitus [% (n/N)] 10.6 (342/3219) 12.0 (129/1073) 3.2 (61/1935) 8.5 (532/6227)
 Family history of early coronary artery  diseasec [% (n/N)] 11.7 (340/2899) 8.7 (93/1073) 7.3 (142/1935) 9.7 (575/5907)
 Current  smokingc [% (n/N)] 33.2 (963/2899) 21.4 (230/1073) 24.7 (491/1988) 28.3 (1684/5960)
 Prior biologic  treatmentc [% (n/N)] 33.1 (961/2899) 20.5 (220/1073) 77.5 (1499/1935) 45.4 (2680/5907)
Baseline concomitant therapies [n (%)]d
 Corticosteroids – 146 (13.6) 728 (36.6) 874 (13.9)
 Immunomodulators – 482 (44.9) 605 (30.4) 1087 (17.3)
 6-MP/AZAe – – 456 (22.9) 456 (7.3)
 Methotrexate – 482 (44.9) 155 (7.8) 637 (10.1)
 Corticosteroids + immunomodulators [n (%)] – 100 (9.3) 201 (10.1) 301 (4.8)
Extent of ustekinumab exposuref
 Ustekinumab-treated patients (N)g 3117 1018 1749 5884
 Ustekinumab exposure [n (%)]
  Single  IVh 0 0 1664 (95.1) –
  At least 6  monthsi 2413 (77.4) 842 (82.7) 849 (48.5) –
  At least 1  yearj 1142 (36.6) 527 (51.8) 464 (26.5) –
 Mean weeks of treatment 26.5 27.7 19.5k 24.6
 Total dose, mg [mean (SD)] 270.4 (122.38) 264.5 (126.34) 432.1 (243.86) 317.4 (184.2)
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3  Results
3.1  Baseline Patient Demographics, Medical 
History, Concomitant Medications
Among 6280 patients enrolled into 12 RCTs, including 3117 
patients with psoriasis, 1018 patients with PsA, and 1749 
patients with CD, most were White (91.2%), 57.9% were 
males, and the mean age was 43.7 years (Table 2). Over-
all, 93.7% of enrolled patients received one or more usteki-
numab doses.
Per the PsA and CD trial designs, concomitant oral 
IMMs (PsA: methotrexate only; CD: azathioprine, 6-mer-
captopurine, methotrexate) and CSs were permitted. Given 
the disparate approaches to conventional treatment, antici-
pated differences between indications were observed in 
commonly used IMMs and overall CS use. Several trials 
enrolled biologic-experienced patients (which typically 
required a 3-month washout) (Table 1), comprising 45.4% 
of integrated patients (psoriasis: 33.1%; PsA: 20.5%; CD: 
77.5%) (Table 2).
Placebo- and ustekinumab-treated patients contributed 
385 PYs and 829 PYs of follow-up, respectively, during 
the initial 8- to 16-week controlled periods, and 674 PYs 
and 4521 PYs of follow-up, respectively, through to year 1. 
Also through year 1, respective mean durations of follow-
up were 17 and 40  weeks (Table  3). Among the 5884 
ustekinumab-treated patients, mean duration of therapy 
was 24.6 weeks (171 days). Additionally, among psoriasis, 
PsA, and CD patients, mean therapy duration was 26.5, 27.7, 
and 19.5 weeks, respectively, and 36.6%, 51.8%, and 26.5% 
of patients, respectively, received ≥ 1 year of ustekinumab 
treatment (Table 2). Most patients with psoriasis received 
subcutaneous ustekinumab (45/90 mg at week 0, week 4, 
and every 12 weeks) for ≥ 6 months and often for ≥ 1 year. 
Most CD patients received a single intravenous infusion 
of ustekinumab (130 mg or weight range-based dosing of 
approximately 6 mg/kg), with nearly half of the patients 
subsequently receiving maintenance subcutaneous usteki-
numab (90 mg every 8 weeks/every 12 weeks). The overall 
cumulative average ustekinumab dose across indications was 
317.4 mg (Table 2).
3.2  Adverse Events (AEs)/Serious AEs, Including 
Infections, and AEs Leading to Study Drug 
Discontinuation
3.2.1  Initial Controlled Period
Combined across indications, 1.6% and 3.4% of usteki-
numab- and placebo-treated patients, respectively, dis-
continued study drug due to AEs. Among all patients, 
incidences/100 PYs (95% CIs) of AEs, SAEs, infections, 
and SIs were comparable between the ustekinumab (594.3 
[577.9–611.2], 16.4 [13.8–19.4], 138.1 [130.2–146.3], 
and 3.3 [2.2–4.7], respectively) and placebo (556.1 
[532.8–580.1], 19.5 [15.3–24.4], 135.8 [124.4–148.0], and 
2.9 [1.4–5.1], respectively) groups. Incidences/100 PYs 
of these events appeared higher in CD than psoriasis/PsA 
patients, regardless of treatment, but were comparable 
between the ustekinumab and placebo groups within each 
indication and across indications combined (Table 3).
3.2.2  Year 1 Analyses
Combined across indications, proportions of patients dis-
continuing study drug due to AEs and incidences/100 PYs 
of AEs, SAEs, infections, and SIs were comparable between 
ustekinumab- and placebo-treated patients through year 1. 
In particular, the respective incidences/100  PYs (95% 
CIs) of infections were 125.4 (122.2–128.7) versus 129.4 
(120.9–138.3). Consistent with initial controlled periods, 
year 1 incidences/100 PYs of these events appeared higher 
among CD patients, regardless of treatment, than psoriasis/
PsA patients (Table 3, Fig. 1). However, incidences were 
comparable between the ustekinumab- and placebo-treated 
CD patients, with no apparent dose effect (Table 4), suggest-
ing that the higher rates were related to underlying moder-
ately-to-severely active CD.
3.2.3  Baseline Medications
Overall, no trends were apparent in the proportions of 
patients with AEs, SAEs, or infections, or patients who dis-
continued study drug due to AEs, when evaluated by base-
line IMM use in the PsA or CD studies where they were per-
mitted. Among ustekinumab-treated patients, the infection 
incidence/100 PYs (95% CI) through year 1 was not mean-
ingfully increased among patients who did versus those who 
did not receive methotrexate at baseline (92.5 [84.2–101.5] 
vs. 115.3 [109.9–121.0], respectively), nor were they sig-
nificantly increased among patients who did versus those 
who did not receive CSs at baseline (116.3 [107.3–125.9] vs. 
107.3 [102.0–112.8], respectively). Few patients had SIs or 
discontinued study drug due to AEs, limiting interpretation 
of these less common events (Table 5).
CD patients generally received higher CS doses (when 
receiving oral systemic CSs [excluding budesonide] at base-
line, the median prednisone dose, or equivalent, was 20 mg/
day) than PsA patients. Nonetheless, no differences between 
CD and PsA ustekinumab-treated patients were identified 
in the occurrence of infections or SIs related to baseline 
CS use. In CD studies, incidences/100 PYs (95% CI) of 
infections and SIs ascribed to periods of placebo treatment 
were 157.1 (136.1–180.5) and 8.6 (4.3–15.5), respectively, 
with CSs, versus 138.1 (123.0–154.6) and 5.9 (3.2–10.1), 
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Table 3  Key safety events/100 PYs of follow-up during the initial placebo-controlled portions and through year 1 of psoriasis, PsA, and CD 
studies
Placebo-controlled periods
Psoriasis (0–12 weeks)a PsA (0–16 weeks)a CD (0–8 weeks)a All patients
Placebo Ustekinumab Placebo Ustekinumab Placebo Ustekinumab Placebo Ustekinumab
Number of patients 
treated
732 1582 379 692 624 1362 1735 3636
Mean weeks of follow-up 12.57 13.37 15.14 15.70 8.15 8.16 11.54 11.86
Mean number of 
 administrationsb
2.21 2.12 2.29 2.20 1.00 1.00 1.79 1.72
D/C study drug due to 
AEs [n (%)]
17 (2.3) 24 (1.5) 15 (4.0) 8 (1.2) 27 (4.3) 26 (1.9) 59 (3.4) 58 (1.6)
PYs of follow-up 177 407 110 209 98 214 385 829
Event rate/100 PYs
 AEs 415.5 511.3 352.4 382.4 1040.4 959.4 556.1 594.3
  95%  CIc 386.0–446.7 489.5–533.7 318.3–389.3 356.4–409.9 977.5–1106.4 918.3–1001.9 532.8–580.1 577.9–611.2
 SAEs 6.8 7.9 12.7 6.2 50.1 42.6 19.5 16.4
  95%  CIc 3.5–11.9 5.4–11.1 6.9–21.3 3.3–10.6 37.1–66.3 34.3–52.3 15.3–24.4 13.8–19.4
 Infectionsd 122.1 141.4 112.3 100.5 187.2 168.4 135.8 138.1
  95%  CIc 106.4–139.5 130.1–153.5 93.4–134.0 87.4–115.1 161.1–216.4 151.5–186.7 124.4–148.0 130.2–146.3
 Serious  infectionsd 1.6 1.2 0.9 0.0 7.2 10.3 2.9 3.3
  95%  CIc 0.4–5.0 0.4–2.9 0.0–5.1 0.0–1.4 2.9–14.8 6.5–15.6 1.4–5.1 2.2–4.7
 Adjudicated serious 
MACE
0.0 1.2 0.9 0.0 0.0 0.0 0.3 0.6
  95%  CIc 0.0–1.7 0.4–2.9 0.0–5.1 0.0–1.4 0.0–3.1 0.0–1.4 0.0–1.5 0.2–1.4
 Deaths 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1
  95%  CIc 0.0–1.7 0.0–1.4 0.0–2.7 0.0–1.4 0.0–3.1 0.0–1.4 0.0–0.8 0.0–0.7
 Malignancies
(excluding NMSC)
0.6 0.3 0.0 0.0 0.0 0.0 0.3 0.1
  95%  CIc 0.0–3.2 0.0–1.4 0.0–2.7 0.0–1.4 0.0–3.1 0.0–1.4 0.0–1.5 0.0–0.7
Through approximately year 1e
Psoriasis PsA CD All patients
Placebof Ustekinumabg Placeboh Ustekinumabi Placeboj Ustekinumabk Placebo Ustekinumab
Number of patients 
treated
733 3117 379 1018 943 1749 2055 5884
Mean weeks of follow-
up
12.93 42.80 19.90 43.40 19.12 32.89 17.05 39.96
Mean weeks of treat-
ment
4.90 26.49 11.96 27.66 9.87 18.80 l 8.41 24.41
D/C study drug due AEs 
[n (%)]
17 (2.3) 86 (2.8) 22 (5.8) 31 (3.0) (4.8) 108 (6.2) 84 (4.1) 225 (3.8)
PYs of follow-up 182 2,566 145 850 347 1,106 674 4,521
Event rate/100 PYs
 AEs 414.8 390.6 343.4 254.2 712.2 641.6 552.4 426.4
  95%  CIc 385.8–445.5 383.0–398.3 313.9–374.9 243.6–265.2 684.3–740.8 626.8–656.7 534.8–570.4 420.4–432.5
 SAEs 8.8 8.8 13.8 9.3 43.8 35.4 27.9 15.4
  95%  CIc 5.0–14.3 7.7–10.0 8.4–21.3 7.4–11.6 37.2–51.4 31.9–39.0 24.1–32.2 14.3–16.6
 Infectionsd 120.7 137.4 102.8 78.0 145.1 134.0 129.4 125.4
  95%  CIc 105.3–137.8 132.9–142.0 86.9–120.6 72.2–84.2 132.7–158.3 127.3–141.0 120.9–138.3 122.2–128.7
 Serious  infectionsd 1.6 1.4 0.7 0.9 6.9 6.4 4.2 2.5
  95%  CIc 0.3–4.8 1.0–1.9 0.0–3.8 0.4–1.9 4.4–10.3 5.0–8.1 2.8–6.0 2.1–3.1
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respectively, without CSs. Respective incidences/100 PYs of 
infections and SIs among ustekinumab-treated patients were 
135.1 (124.0–146.9) and 6.4 (4.2–9.4) with CSs, and 133.4 
(129.0–142.2) and 6.4 (4.7–8.6) without CSs. In addition, 
among CD patients, incidences/100 PYs of SAEs and SIs 
appeared higher in placebo patients receiving methotrex-
ate versus those not receiving methotrexate, and the same 
was true, although to a lesser extent, in ustekinumab-treated 
patients (Table 5). When considering all IMM use (including 
6-mercaptopurine/azathioprine), no effect was apparent on 
the short- or long-term safety profile of ustekinumab versus 
placebo among CD patients (Table 6).
3.3  Deaths
Through year  1, five ustekinumab–treated psoriasis 
patients, and no CD or PsA patients, died. The overall 
incidence/100 PYs (95% CI) of death was 0.1 (0.0–0.3) 
and 0.0 (0.0–0.4), respectively, among ustekinumab- and 
placebo-treated patients (Table 3). One patient each died 
due to dilated cardiomyopathy (ustekinumab 90 mg) [6], 
aspiration following alcohol intoxication (in a patient who 
received placebo followed by ustekinumab 45 mg) [6], and 
multisystem organ failure (ustekinumab 90 mg) [7]; two 
deaths were accidental (gunshot wound, motor vehicle acci-
dent). All deaths were considered unrelated to ustekinumab 
treatment by the investigators.
3.4  AEs of Special Interest
3.4.1  Opportunistic Infections
Combined across indications, the overall number of OIs 
was low through year 1; no single OI occurred in more than 
one patient, except non-serious esophageal candidiasis in 
two placebo-treated and three ustekinumab-treated CD 
patients. Three serious OIs occurred among ustekinumab-
treated patients, including disseminated histoplasmosis (CD 
Table 3  (continued)
Through approximately year 1e
Psoriasis PsA CD All patients
Placebof Ustekinumabg Placeboh Ustekinumabi Placeboj Ustekinumabk Placebo Ustekinumab
 Adjudicated serious 
MACE
0.6 0.6 0.7 0.7 0.0 0.1 0.3 0.5
  95%  CIc 0.0–3.1 0.3–0.9 0.0–3.8 0.3–1.5 0.0–0.9 0.0–0.5 0.0–1.1 0.3–0.7
 Deaths 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1
  95%  CIc 0.0–1.6 0.1–0.5 0.0–2.1 0.0–0.4 0.0–0.9 0.0–0.3 0.0–0.4 0.0–0.3
 Malignancies (exclud-
ing NMSC)
0.6 0.4 0.0 0.1 0.0 0.4 0.2 0.4
  95%  CIc 0.0–3.1 0.2–0.8 0.0–2.1 0.0–0.7 0.0–0.9 0.1–0.9 0.0–0.8 0.2–0.6
AEs adverse events, CD Crohn’s disease, CI confidence interval, D/C discontinuation, IV intravenous, MACE major adverse cardiovascular 
event, NMSC non-melanoma skin cancer, PsA psoriatic arthritis, PYs patient-years, SAE serious adverse event, SC subcutaneous
a Psoriasis—phase II, PHOENIX-1, PHOENIX-2; PsA—phase II, PSUMMIT-1, PSUMMIT-2; CD—phase IIa (only placebo-controlled IV pop-
ulation), CERTIFI, UNITI-1, UNITI-2
b SC administration in psoriasis and PsA trials; IV administration in CD trials
c CIs based on an exact method assuming the observed number of events follows a Poisson distribution
d Infection as assessed by the investigator
e Psoriasis—phase II, PHOENIX-1, PHOENIX-2, ACCEPT (all through week 52); PsA—phase II (through week 36), PSUMMIT-1 (through 
week 52), PSUMMIT-2 (through week 60); CD—phase IIa (only placebo-controlled IV population in population 1; through week 28), CERTIFI 
(through week 36), UNITI-1 and UNITI-2 (through week 8 for patients who entered IM-UNITI; through week 20 for patients who did not enter 
IM-UNITI), IM-UNITI (through week 44)
f Includes data up to the time of crossover, and does not include etanercept patients in ACCEPT
g Includes data from the first ustekinumab dose onward for patients who crossed over from placebo
h Includes data up to the time of early escape or crossover
i Includes data from the first ustekinumab dose onward for patients who escaped early or crossed over from placebo
j Includes data up to the first ustekinumab dose for patients who were initially treated with placebo; includes data on or after 16 weeks from the 
first (and last) ustekinumab dose for patients who were initially treated with ustekinumab and were then crossed over or re-randomized to pla-
cebo
k Includes data up to 16 weeks from the first ustekinumab dose for patients who were crossed over or re-randomized to placebo
l Excludes periods of placebo treatment among some ustekinumab responders who were re-randomized to placebo at maintenance and subse-
quently resumed ustekinumab treatment following loss of response
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patient [21] receiving concomitant CSs/azathioprine, spik-
ing fevers prior to randomization, discontinued infliximab 
10 mg/kg 3 months prior), Listeria meningitis (CD patient, 
field worker, treated with prednisone 30 mg/day 3 weeks 
after ustekinumab 6 mg/kg [11]), and herpes zoster (pso-
riasis patient, left T8 dermatome affected, 19 disseminated 
cutaneous vesicles) [5].
3.4.2  Tuberculosis Infection
Combined across indications through year 1, one case of 
presumed active primary TB was reported in a 31-year-old 
Hungarian man with CD, approximately 10 months after 
receiving a single intravenous ustekinumab dose (130 mg) 
[11]. This patient had previously received a Bacillus Calmette 
Guerin vaccination and had negative chest radiograph and 
QuantiFERON findings at screening. The patient reported 
flu-like symptoms (fever, chills, sore throat, cough, yellowish 
sputum). QuantiFERON, sputum smear, and M. tuberculosis 
culture were negative, and chest radiograph and computed 
tomography findings were consistent with TB. Following 
empirical triple anti-TB therapy, the symptoms resolved.
3.4.3  Serious Major Adverse Cardiovascular Events
Across studies, incidences/100 PYs (95% CIs) of adjudi-
cated serious MACEs during the initial 8- to 16-week con-
trolled periods were 0.6 (0.2–1.4) and 0.3 (0.0–1.5), respec-
tively, among patients receiving ustekinumab (n = 5) and 
placebo (n = 1). Limited numbers of events and short dura-
tion of follow-up may constrain data interpretation. Across 
Psoriasisa
Infections
requiring
treatment
Serious
infections
0
100
200
300
400
500
600
700
800
Ev
e
n
t r
at
e 
pe
r 1
00
PY
414.8 390.6
8.8 8.8
120.7 137.4
31.8 27.1
1.6 1.4
Psoriatic Arthritisb
Infections
requiring
treatment
Serious
infections
0
100
200
300
400
500
600
700
800
Ev
e
n
t r
at
e 
pe
r 1
00
PY
Crohn’s Diseasec
Infections
requiring
treatment
Serious
infections
0
100
200
300
400
500
600
700
800
Ev
e
n
t r
at
e 
pe
r 1
00
PY
AEs SAEs Infections AEs SAEs Infections
AEs SAEs Infections AEs SAEs Infections
All Patientsd
Infections
requiring
treatment
Serious
infections
0
100
200
300
400
500
600
700
800
Ev
e
n
t r
at
e 
pe
r 1
00
PY
343.4
254.2
13.8 9.3
102.8 78.0
35.2 23.5 0.7 0.9
712.2
641.6
43.8 35.4
145.1 134.0
54.8 43.5
6.9 6.4
552.4
426.4
27.9 15.4
129.4 125.4
44.4 30.5 4.2 2.5
Placebo Ustekinumab
Fig. 1  Incidence rates/100 PYs of AEs, SAEs, and infections among 
ustekinumab- and placebo-treated patients through up to year 1 in 
phase II/III studies of a psoriasis, b psoriatic arthritis, c Crohn’s dis-
ease, and d combined across all indications. PYs patient-years, AEs 
adverse events, SAEs serious adverse events
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studies, incidences/100 PYs (95% CIs) of serious MACEs 
were also similar through year 1 among patients receiving 
ustekinumab (0.5 [0.3–0.7]; 21 events) and placebo (0.3 
[0.0–1.1]; 2 events) (Table 3). The incidence/100 PYs of 
serious MACEs appeared lower in CD patients (one event) 
versus psoriatic patients, likely owing to higher rates of 
underlying cardiovascular risk factors (e.g. hypertension, 
hyperlipidemia, diabetes, obesity, smoking) and older age 
in the latter (Table 2).
3.4.4  Malignancies
Low and comparable incidences/100  PYs (95% CI) of 
NMSC were observed among ustekinumab-treated patients 
through year 1 (n = 30, 0.7 [0.5–1.0]) and placebo-treated 
patients (n = 4, 0.6 [0.2–1.5]). Most NMSCs occurred in 
psoriasis patients who were older, commonly received pho-
totherapy, and might self-treat with natural sunlight, in both 
the ustekinumab (n = 24, 0.9/100 PYs [0.6–1.4]) and placebo 
(n = 2, 1.1/100 PYs [0.1–4.0]) groups (Table 7).
Through year 1, incidences/100 PYs of malignancies 
other than NMSC were also low and comparable among 
ustekinumab-treated (n = 15, 0.4 [0.2–0.6]) and placebo-
treated (n = 1, 0.2 [0.0–0.8]) patients, with overlapping 
95% CIs (Table  7). As with NMSC, most non-NMSC 
malignancies occurred in psoriasis patients (ustekinumab: 
n = 11, 0.4/100 PYs [0.2–0.8]; placebo: n = 1, 0.6/100 PYs 
[0.0–3.1]). All non-NMSC malignancies were solid tumors 
except one cutaneous T-cell lymphoma (mycosis fungoi-
des retrospectively concluded to pre-exist but that was 
incorrectly diagnosed as psoriasis [7]), chronic lymphocytic 
leukemia in a psoriasis patient treated with ustekinumab 
90 mg, and multiple myeloma in a CD patient treated with 
intravenous ustekinumab (6 mg/kg) and who had a 6-year 
history of monoclonal gammopathy of unknown significance 
[11].
Combined across indications, the SIRs (95% CIs) for 
malignancies (excluding cervical cancers in situ and NMSC 
per SEER) in the ustekinumab and placebo groups were 0.6 
(0.3–1.0) and 0.3 (0.0–1.9), respectively, with overlapping 
95% CIs. Within-indication results were similar (Table 7). 
Data interpretation is limited by small numbers of events, 
relatively short duration of exposure, and differences in the 
length of treatment/follow-up.
3.4.5  Hypersensitivity Reactions
No serious anaphylactic reactions or serum sickness-like reac-
tions to ustekinumab were observed. Two CD patients dis-
played signs/symptoms of hypersensitivity temporally asso-
ciated with treatment (throat tightness/shortness of breath/
flushing after the first and only subcutaneous ustekinumab 
administration; chest discomfort/flushing/urticaria/fever after 
the initial intravenous ustekinumab dose). Symptoms resolved 
within 1 h following oral CS/antihistamine treatment.
3.4.6  Neurological Disorders Other Than Stroke
Serious neurological disorders were rare, with  no cases of 
reversible posterior leukoencephalopathy syndrome (RPLS), 
definitive progressive multifocal leukoencephalopathy, 
Table 4  Key safety findings by dose among randomized and treated CD patients
q8w every 8 weeks, q12w every 12 weeks, AEs adverse events, CD Crohn’s disease, D/C discontinuation, IV intravenous, SAEs serious adverse 
events, SC subcutaneous
a Patients who were in clinical response to ustekinumab IV induction dosing and were randomized to placebo SC on entry into the maintenance 
study
b Includes data up to the time of dose adjustment (i.e., time of meeting loss-of-response criteria)
c Infection as assessed by the investigator
Through week 8 of UNITI-1 and UNITI-2 Through week 44 or time of dose adjustment in IM-UNITI
Ustekinumab Ustekinumabb
Placebo 130 mg IV 6 mg/kg IV Combined Placebo  SCa,b 90 mg SC q12w 90 mg SC q8w Combined
Number of patients randomized 
and treated
466 471 470 941 133 132 131 263
Mean weeks of follow-up 8.18 8.22 8.16 8.19 32.0 36.6 35.2 35.9
Number (%) of patients with:
 AEs 282 (60.5) 275 (58.4) 284 (60.4) 559 (59.4) 111 (83.5) 106 (80.3) 107 (81.7) 213 (81.0)
 SAEs 28 (6.0) 23 (4.9) 25 (5.3) 48 (5.1) 20 (15.0) 16 (12.1) 13 (9.9) 29 (11.0)
 Infectionsc 108 (23.2) 92 (19.5) 111 (23.6) 203 (21.6) 66 (49.6) 61 (46.2) 63 (48.1) 124 (47.1)
 Serious  infectionsc 6 (1.3) 7 (1.5) 8 (1.7) 15 (1.6) 3 (2.3) 7 (5.3) 3 (2.3) 10 (3.8)
 D/C study drug due to AEs 19 (4.1) 8 (1.7) 8 (1.7) 16 (1.7) 8 (6.0) 10 (7.6) 4 (3.1) 14 (5.3)
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or demyelinating disorder through year 1, apart from one 
non-serious event of ‘other demyelinating diseases of the 
central nervous system’. The CD patient experienced dizzi-
ness, numbness, and mouth tingling starting approximately 
2 months after entering the maintenance study, as well as 
visual symptoms. Although imaging studies identified 
microvascular disease and previous small vessel insults, 
demyelinating disease was reported as a diagnosis of exclu-
sion. One previously reported RPLS case in the PHOENIX-2 
trial occurred after approximately 2.5 years of ustekinumab 
treatment, the only such event across combined indications 
[25].
4  Discussion
This is the first integrated analysis of safety data derived 
from phase II/III trials combined across the ustekinumab-
approved indications. Safety data from 5884 ustekinumab-
treated patients are reported (including 1659 patients after 
crossover from placebo); 2055 patients received placebo 
comparator through the initial 8- to 16-week controlled 
periods.
The ustekinumab safety profile was comparable with 
that of placebo when integrated across indications, with no 
evidence of a dose effect in the occurrence of AEs, SAEs, 
or infections. Importantly, 70% and 36% of ustekinumab-
treated patients received ≥ 6 months and ≥ 1 year, respec-
tively, of treatment (4521 PYs of follow-up; mean usteki-
numab treatment duration: 24.6 weeks). Exposure-adjusted 
rates of AEs of special interest through year 1 were generally 
consistent with those observed during the initial controlled 
periods. These findings are consistent with those of clinical 
trial extensions through up  to 5 years in psoriasis, and up to 
2 years in PsA, which showed no increase in the risk of SI, 
death, MACEs, or malignancy [10, 12, 13].
In the current analysis, ustekinumab also demonstrated 
a favorable benefit–risk profile in CD, with single initial 
dosing up to 6 mg/kg intravenously, followed by 90 mg sub-
cutaneously every 8/12 weeks. AE incidences/100 PYs were 
comparable between treatment arms, with no evidence of a 
dose effect. Reassuringly, evaluation of ustekinumab in CD 
patients through year 1 did not alter the overall ustekinumab 
safety profile previously defined in patients with psoriatic 
diseases, despite inherent differences between disease states 
and frequent use of concomitant IMMs/CSs in CD.
Notably, AEs, SAEs, infections, and SIs were more com-
mon in CD trials than psoriasis/PsA trials, which likely 
reflects the more significant disease burden, inherently 
greater risk of infection, and/or more common CS/IMM 
use in CD populations than psoriatic populations. For exam-
ple, the effect of CSs in CD patients was illustrated by an 
apparently higher incidence/100 PYs of infections among 
placebo-treated CD patients than ustekinumab-treated CD 
patients with baseline CS use. However, regardless of CS 
exposure, no increase in the time-adjusted occurrence of 
infections or SIs was observed among ustekinumab-treated 
patients. Additionally, given the overall low number of 
potential OIs, and accounting for the potential confounder 
of IMM/CS use, no association was apparent between 
Table 6  Key safety findings in 
CD studies, by baseline IMM 
use
Phase II (only controlled IV  patientsin population 1; through week 28), CERTIFI (through week 36), 
UNITI-1 and UNITI-2 (through week 8 for patients who entered IM-UNITI; through week 20 for patients 
who did not enter IM-UNITI, IM-UNITI (through week 44)
AEs adverse events, CD Crohn’s disease, IMM immunomodulators, IV intravenous, SAEs serious adverse 
events
IMMs included 6-mercaptopurine, azathioprine, or methotrexate
a Includes data up to the time of early escape or crossover
b Includes data from the first ustekinumab dose onward for patients who escaped early or crossed over from 
placebo
c Infection as assessed by the investigator
Induction (through week 8) Maintenance (through week 44)
Placeboa Ustekinumabb Placeboa Ustekinumabb
+IMM −IMM +IMM −IMM +IMM −IMM +IMM −IMM
Number of patients treated 195 429 410 952 70 136 112 223
Mean weeks of follow-up 8.2 8.1 8.1 8.2 27.2 24.7 33.4 30.3
Percentage of patients 
with one or more:
 AEs 56.4 66.0 57.8 62.6 77.1 81.6 72.3 79.8
 SAEs 8.7 5.4 3.9 5.9 11.4 11.8 9.8 9.9
 Infectionsc 26.2 22.4 18.8 23.1 40.0 41.9 41.1 42.6
 Deaths 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Ustekinumab Safety Through 1 Year
ustekinumab treatment and increased risk of OIs, includ-
ing TB. The proportion (95% CI) of ustekinumab-treated 
patients with active TB across all phase II/III studies for 
approved indications was considerably lower (0.02/100 PYs 
[0.0–0.06]) than in the clinical development programs for 
golimumab (0.24/100 PYs [0.16–0.33]) and infliximab 
(0.39/100 PYs [0.25–0.57]) [26].
Table 7  Patients with one or more malignancies/100 PYs through year 1 in psoriasis, PsA, and CD studies
Psoriasis—phase II, PHOENIX-1, PHOENIX-2, ACCEPT (all through week 52); PsA—phase II (through week 36), PSUMMIT-1 (through 
week 52), PSUMMIT-2 (through week 60); CD—phase IIa (only controlled IV population in population 1; through week 28), CERTIFI (through 
week 36), UNITI-1 and UNITI-2 (through week 8 for patients who entered IM-UNITI; through week 20 for patients who did not enter IM-
UNITI), IM-UNITI (through week 44)
CD Crohn’s disease, CI confidence interval, IV intravenous, NMSC non-melanoma skin cancer, PsA psoriatic arthritis, PYs patient-years, SEER 
Surveillance, Epidemiology, and End Results, SIR standardized incidence ratio
a Includes data up to the time of crossover
b Includes data from the first ustekinumab dose onward for patients who crossed over from placebo
c Includes data up to the time of early escape or crossover
d Includes data from the first ustekinumab dose onward for patients who escaped early or crossed over from placebo
e Includes data up to the first ustekinumab dose for patients who were initially treated with placebo; includes data on or after 16 weeks from the 
first ustekinumab dose for patients who were initially treated with ustekinumab and were crossed over or re-randomized to placebo
f Includes data up to 16 weeks from the first ustekinumab dose for patients who were crossed over or re-randomized to placebo
g CIs based on an exact method assuming that the observed number of events follows a Poisson distribution
h Only patients of White, Black or African American, Asian, American Indian/Alaska Native, Native Hawaiian or other Pacific Islander race were 
included since SEER only contains incidence rates for these populations
i Expected number of patients with malignancies is based on the SEER database (year 2013), adjusted for age, sex, and race
j SIR determined as observed, divided by the expected numbers of patients with malignancies
Psoriasis PsA CD All patients
Comparatora Ustekinumabb Placeboc Ustekinumabd Placeboe Ustekinumabf Comparator Ustekinumab
Number of patients treated 733 3117 379 1018 943 1749 2055 5884
NMSC
 Total (median) PYs of 
follow-up
182 (0.2) 2558 (0.9) 145 (0.4) 849 (1.0) 346 (0.2) 1105 (0.6) 673 (0.2) 4512 (0.8)
 Patients with event/inci-
dence/100 PYs
2/1.1 24/0.9 0/0.0 2/0.2 2/0.6 4/0.4 4/0.6 30/0.7
 95%  CIg (0.1–4.0) (0.6–1.4) (0.0–2.1) (0.0–0.9) (0.1–2.1) (0.1–0.9) (0.2–1.5) (0.5–1.0)
Malignancies excluding NMSC 
and in situ cervical cancer
 Total (median) PYs of 
follow-up
182 (0.2) 2563 (0.9) 145 (0.4) 849 (1.0) 347 (0.2) 1106 (0.6) 674 (0.2) 4519 (0.8)
 Patients with event/inci-
dence/100 PYs
1/0.6 11/0.4 0/0.0 1/0.1 0/0.0 3/0.3 1/0.2 15/0.3
 95%  CIg (0.0–3.1) (0.2–0.8) (0.0–2.1) (0.0–0.7) (0.0–0.9) (0.1–0.8) (0.0–0.8) (0.2–0.6)
All malignancies
 Total (median) PYs of 
follow-up
181 (0.2) 2556 (0.9) 145 (0.4) 849 (1.0) 346 (0.2) 1105 (0.6) 673 (0.2) 4510 (0.8)
 Patients with event/inci-
dence/100 PYs
3/1.7 35/1.4 0/0.0 3/0.4 2/0.6 7/0.6 5/0.7 45/1.0
 95%  CIg (0.3–4.8) (1.0–1.9) (0.0–2.1) (0.1–1.0) (0.1–2.1) (0.3–1.3) (0.2–1.7) (0.7–1.3)
Patients included in SEER 
 analysish
722 3033 373 1005 914 1689 2009 5727
 Total (median) PYs of 
follow-up
179 (0.2) 2497 (0.9) 143 (0.5) 839 (1.0) 334 (0.2) 1068 (0.6) 656 (0.2) 4403 (0.8)
 Observed/expectedi patients 
with event
1/1.0 10/13.2 0/0.9 1/4.9 0/1.2 2/3.6 1/3.0 13/21.7
 SIRj 1.1 0.8 0.0 0.2 0.0 0.6 0.3 0.6
 SIR 95%  CIg (0.0–5.8) (0.4–1.4) (0.0–3.5) (0.0–1.1) (0.0–2.6) (0.1–2.0) (0.0–1.9) (0.3–1.0)
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A theoretical risk of malignancy for IL-12/23 inhibitors, 
such as ustekinumab, was based on animal models suggest-
ing involvement of IL-12 in tumor surveillance (e.g. stud-
ies in IL-12p35 knockout mice) [1, 27, 28]. While no dedi-
cated preclinical carcinogenicity studies were conducted for 
ustekinumab, in part due to limited cross-species reactivity, 
all available (including long-term) safety data in humans 
have indicated no safety signals for malignancy with usteki-
numab [12, 15, 16, 29]. Additionally, comparing malig-
nancy incidence between ustekinumab-treated patients and 
the general US population (via the SEER database) in these 
integrated analyses suggested no increased malignancy risk, 
either combined across, or within, indications. Malignancy 
incidence among ustekinumab-treated psoriasis patients 
through year 1 (0.4/100 PYs) was also consistent with usteki-
numab safety data through 5 years of follow-up in psoriasis 
clinical trials (0.6/100 PYs) [12] and with real-world expe-
rience in PSOLAR, with a median follow-up of 4.2 years 
(0.6/100 PYs) [29]. Furthermore, in a nested case-control 
analysis of PSOLAR data, no overall increased malignancy 
risk was observed for any duration of ustekinumab treatment 
(> 0 to < 3 months, ≥ 3 to < 12 months, ≥ 12 months) versus 
no ustekinumab treatment [29]. While current and previ-
ously reported findings are reassuring, longer-term longitu-
dinal data and larger (e.g. real-world observational) studies 
will be needed to confirm current findings of no increased 
malignancy risk with IL-12/23 inhibition.
Historically, the sponsor has evaluated serious MACEs 
in psoriatic patients who have increased risk for occlusive 
vascular diseases [30, 31], likely resulting from higher rates 
of cardiovascular risk factors (hypertension, hyperlipidemia, 
diabetes, obesity, smoking) and the disease itself represent-
ing an independent risk factor [32]. In a systematic review 
and meta-analysis of 11 observational studies (n = 32,973), 
cardiovascular and cerebrovascular morbidity were 
increased by 43% and 22%, respectively, in PsA patients 
versus the general population [33]. In our integrated analy-
sis, consistent with observations through 5 years in psoriasis 
patients [12, 13] and 2 years in PsA patients [10] partici-
pating in ustekinumab RCT long-term extensions, overall 
rates of serious MACEs were low and generally comparable 
between treatment groups, with no consistent evidence that 
ustekinumab increases the risk of serious MACEs. As might 
be expected, CD patients appeared to exhibit fewer predis-
posing risk factors (Table 2) and had lower rates of serious 
MACEs, with only one event reported through year 1.
These integrated analyses are not without limitations. In 
the context of chronic lifelong conditions, 1 year could be 
considered a relatively short duration of treatment and/or 
follow-up. In addition, the duration of treatment and follow-
up were considerably different between placebo and usteki-
numab cohorts across studies. This led to relatively small 
numbers of some AEs of interest among placebo-treated 
patients, and in turn limited interpretation of comparisons 
between treatment groups despite adjustments for follow-up 
duration. Nonetheless, it is not clear whether these safety 
analyses were imbued with any systemic bias.
Despite these limitations, these integrated analyses rep-
resent a substantially larger, prospectively collected, safety 
experience than any individual practitioner, investigator, 
or institution will have at their disposal for some time. 
Although possibly insufficient to assess long latency events, 
such as malignancies, the year 1 data reasonably represent 
the ustekinumab safety profile for most other potential com-
mon risks of interest, as data were consistent with longer-
term safety data from the psoriasis/PsA trials. Of note, lim-
iting this analysis to data accrued over 1 year of treatment 
and follow-up ensured that the more extensive safety data 
available in psoriasis patients did not overshadow more lim-
ited data available for the PsA and CD populations. Lastly, 
the 1-year timeframe provides an intuitive and tangible 
context for practitioners regarding the ustekinumab benefit-
risk profile in treating these immune-mediated inflammatory 
disorders.
5  Conclusions
Through year 1, across 12 phase II/III RCTs in psoriasis, 
PsA, and CD, ustekinumab demonstrated a favorable safety 
profile that was generally consistent with placebo and 
longer-term data from psoriasis trials. Future studies with 
even larger numbers of patients from real-world observa-
tional databases/registries, ideally followed over multiple 
years of treatment, are needed to validate findings and fur-
ther evaluate rare events.
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